Jesús
San Miguel Izquierdo
Consultor Investigador
Hospital Duran i Reynals
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Hospital Duran i Reynals (3)
2021
-
Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- And high-risk myeloma
Blood, Vol. 137, Núm. 1, pp. 49-60
2020
-
Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality
Blood Cancer Journal, Vol. 10, Núm. 10
2003
-
High-dose therapy in diffuse large cell lymphoma: Results and prognostic factors in 452 patients from the GEL-TAMO Spanish cooperative group
Annals of Oncology, Vol. 14, Núm. 1, pp. 140-151